Aardvark Therapeutics, Inc. (AARD)

NASDAQ: AARD · Real-Time Price · USD

3.940

+0.040 (1.03%)

At close: Apr 10, 2026, 4:00 PM EDT

3.970

+0.030 (0.76%)

After-hours: Apr 10, 2026, 5:51 PM EDT

Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	13.79	5.31	2.17	2.7
Research & Development	48.94	17.36	4.48	7.17
Other Operating Expenses	-	0.12	0.76	1.49
Total Operating Expenses	62.73	22.79	7.42	11.36
Operating Income	-62.73	-22.79	-7.42	-11.36
Interest Income	5.14	2.41	1.42	0.12
Other Non-Operating Income (Expense)	-0.01	-0.22	-1.22	-2.32
Total Non-Operating Income (Expense)	5.13	2.2	0.21	-2.2
Pretax Income	-57.59	-20.59	-7.21	-13.56
Net Income	-57.59	-20.59	-7.21	-13.56
Net Income to Common	-57.59	-20.59	-7.21	-13.56
Shares Outstanding (Basic)	20	4	4	4
Shares Outstanding (Diluted)	20	4	4	4
Shares Change (YoY)	391.06%	0.90%	1.78%	-
EPS (Basic)	-2.93	-5.15	-1.82	-3.49
EPS (Diluted)	-2.93	-5.15	-1.82	-3.49
Shares Outstanding	21.82	-	-	-
Free Cash Flow	-54.27	-18.2	-5.82	-5.82
Free Cash Flow Per Share	-2.77	-4.55	-1.47	-1.50
EBITDA	-62.69	-22.77	-7.42	-11.36
EBIT	-62.73	-22.79	-7.42	-11.36

Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q